发布求助
文献互助 智能选刊 最新文献

Biotechnology healthcare最新文献

筛选
英文 中文
Connecting Patients With Specialty Products: Part 2: The future of specialty drug distribution. 将患者与专业产品联系起来:第2部分:专业药物分销的未来。
Biotechnology healthcare Pub Date : 2012-01-01
Jack McCain
{"title":"Connecting Patients With Specialty Products: Part 2: The future of specialty drug distribution.","authors":"Jack McCain","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Previously, this series described distribution channels through which specialty drugs move to patients. This installment discusses changes and challenges that lie ahead, especially at the dispensing end.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 3","pages":"13-6"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474456/pdf/bh0903013.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30995273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Will comparative effectiveness research finally succeed? 比较有效性研究最终会成功吗?
Biotechnology healthcare Pub Date : 2012-01-01
Erwin A Blackstone, Joseph P Fuhr, Danielle Ziernicki
{"title":"Will comparative effectiveness research finally succeed?","authors":"Erwin A Blackstone,&nbsp;Joseph P Fuhr,&nbsp;Danielle Ziernicki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Autonomy, innovation, and drug access may be at stake along with personalized medicine. Can all stakeholders be satisfied and should cost be a factor?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 3","pages":"22-6"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474453/pdf/bh0903022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30995275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myriad: debate over gene patents continues. Myriad:关于基因专利的争论仍在继续。
Biotechnology healthcare Pub Date : 2012-01-01
Joanna T Brougher
{"title":"Myriad: debate over gene patents continues.","authors":"Joanna T Brougher","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 3","pages":"29-30"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474457/pdf/bh0903029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30995276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The accelerated approval debate: faster FDA drug approvals may mean less efficacy data. 加速审批辩论:FDA更快的药物审批可能意味着更少的疗效数据。
Biotechnology healthcare Pub Date : 2012-01-01
John Carroll
{"title":"The accelerated approval debate: faster FDA drug approvals may mean less efficacy data.","authors":"John Carroll","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 2","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411233/pdf/bh0902006.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30821324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Part 1: Distribution models for biologics and other specialty pharmaceutical products: In this first of a two-part series, we examine the distribution landscape for specialty pharmaceuticals. A manufacturer's strategy for the flow of product to patient has important implications for payers and for the success of a new biologic therapy. 第1部分:生物制剂和其他特种药品的分销模型:在两部分系列的第一部分中，我们将研究特种药品的分销前景。制造商的产品流向患者的策略对支付者和新生物疗法的成功具有重要意义。
Biotechnology healthcare Pub Date : 2012-01-01
Jack McCain
{"title":"Part 1: Distribution models for biologics and other specialty pharmaceutical products: In this first of a two-part series, we examine the distribution landscape for specialty pharmaceuticals. A manufacturer's strategy for the flow of product to patient has important implications for payers and for the success of a new biologic therapy.","authors":"Jack McCain","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 2","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411231/pdf/bh0902008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30821325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Next Generation Sequencing: The Next Iteration of Personalized Medicine: Next generation sequencing, along with expanding databases like The Cancer Genome Atlas, has the potential to aid rational drug discovery and streamline clinical trials. 下一代测序:个性化医疗的下一个迭代:下一代测序，以及不断扩展的数据库，如癌症基因组图谱，有可能帮助合理的药物发现和简化临床试验。
Biotechnology healthcare Pub Date : 2012-01-01
Bob Carlson
{"title":"Next Generation Sequencing: The Next Iteration of Personalized Medicine: Next generation sequencing, along with expanding databases like The Cancer Genome Atlas, has the potential to aid rational drug discovery and streamline clinical trials.","authors":"Bob Carlson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 2","pages":"21-5"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411229/pdf/bh0902021.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30821328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum? 为标签外使用生物制剂设定更高的标准:在医生努力寻求最佳治疗的过程中，标签外使用生物制剂很常见。病人想要任何有效的方法。制药商希望扩大标签，但纳税人对缺乏疗效数据感到恼火。这个难题有答案吗?
Biotechnology healthcare Pub Date : 2011-01-01
Ed Silverman
{"title":"Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum?","authors":"Ed Silverman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Off-label use of biologics is common as physicians strive to treat patients as best they can. But payers and purchasers want evidence of value before they pay for off-label use, and the FDA has moved to mitigate off-label prescribing. With patient activism increasing, how should off-label use be handled? And where do the drug makers fit in?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 3","pages":"14-8"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278115/pdf/bh0803014.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Conversation With Scott Gottlieb, MD: The impact of health care reform on access to biologics, health policy, and managed care. Scott Gottlieb博士:医疗改革对获得生物制剂、卫生政策和管理式医疗的影响。
Biotechnology healthcare Pub Date : 2011-01-01
Michael D Dalzell
{"title":"A Conversation With Scott Gottlieb, MD: The impact of health care reform on access to biologics, health policy, and managed care.","authors":"Michael D Dalzell","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The former CMS and FDA insider talks about the many challenges that plague the financing of healthcare and what is needed to get affordable patient care on track.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 3","pages":"19-22"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278114/pdf/bh0803019.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing MS: Trends, Issues, and Perspectives. 管理MS:趋势、问题和前景。
Biotechnology healthcare Pub Date : 2011-01-01
Mari Edlin, Peter Sonnenreich
{"title":"Managing MS: Trends, Issues, and Perspectives.","authors":"Mari Edlin,&nbsp;Peter Sonnenreich","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The entry of oral medications for multiple sclerosis into the marketplace and the high cost of biologic drugs are presenting new challenges for stakeholders.</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 2","pages":"22-6"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138383/pdf/bth08_2p022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30555154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renewing Humans: Regenerative medicine is set for explosive growth. Proponents believe that some of the advances in this field will evolve into therapeutic practices that will forever change healthcare. 再生人类:再生医学将迎来爆发式增长。支持者认为，该领域的一些进步将演变为将永远改变医疗保健的治疗实践。
Biotechnology healthcare Pub Date : 2011-01-01
Bob Carlson
{"title":"Renewing Humans: Regenerative medicine is set for explosive growth. Proponents believe that some of the advances in this field will evolve into therapeutic practices that will forever change healthcare.","authors":"Bob Carlson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Some pioneers in this burgeoning field say that regenerative therapies will forever change healthcare and provide a fourfold return on investment. Hope? Or hype?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 4","pages":"17-20"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278127/pdf/bh0804017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30553409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信